Squarepoint Portfolio holdings
Squarepoint runs funds that use computer models to trade many kinds of assets around the world. It began as nQuant, a trading unit set up inside Lehman Brothers in 2000 by its founders, Olivier Durantel and Gregoire Schneider. Barclays took over nQuant in 2008, and in December 2014 it was spun off as an independent firm and renamed Squarepoint. In 2022 Squarepoint formed STG, a separate trading group that shares much of its infrastructure but has its own investment staff, and in 2021 it partnered with Arini Capital, a European hedge fund.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Taiwan ETF
EWT
|
+$89.9M |
| 2 |
VanEck Gold Miners ETF
GDX
|
+$71.9M |
| 3 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$69M |
| 4 |
iShares China Large-Cap ETF
FXI
|
+$66M |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
+$58.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
|
+$33M |
| 2 |
Altria Group
MO
|
+$32.4M |
| 3 |
iShares MSCI EAFE ETF
EFA
|
+$26.5M |
| 4 |
CVS Health
CVS
|
+$24.7M |
| 5 |
Medtronic
MDT
|
+$22.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 17.23% |
| 2 | Technology | 14.6% |
| 3 | Healthcare | 11.36% |
| 4 | Industrials | 11.26% |
| 5 | Consumer Discretionary | 10.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1451
Northern Oil and Gas
NOG
$2.42B
| $58K | ﹤0.01% |
4,175
+681
| +19% | +$13.2K |
2015 Q4
6 quarters
|
|
1452
Acacia Research
ACTG
$415M
| $57K | ﹤0.01% |
13,900
-14,431
| -51% | -$67.2K |
2016 Q4
2 quarters
|
|
1453
DRDGold
DRD
$2.21B
| $57K | ﹤0.01% |
+17,984
| New | +$67.7K |
2017 Q2
0 quarters
|
|
|
ECYT
1454
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $57K | ﹤0.01% |
+37,811
| New | +$81.2K |
2017 Q2
0 quarters
|
|
|
EGLT
1455
DELISTED
Egalet Corporation
EGLT
| $55K | ﹤0.01% |
+23,105
| New | +$73.8K |
2017 Q2
0 quarters
|
|
1456
B2Gold
BTG
$7.11B
| $54K | ﹤0.01% |
19,225
-348,899
| -95% | -$920K |
2017 Q1
1 quarter
|
|
1457
DELISTED
TerraForm Global, Inc. Class A Common Stock
GLBL
| $53K | ﹤0.01% |
+10,500
| New | +$50.8K |
2017 Q2
0 quarters
|
|
1458
DELISTED
Kineta, Inc. Common Stock
KA
| $51K | ﹤0.01% |
78
-41
| -34% | -$29.2K |
2016 Q4
2 quarters
|
|
1459
Arrowhead Research
ARWR
$8.22B
| $49K | ﹤0.01% |
+30,398
| New | +$49.2K |
2017 Q2
0 quarters
|
|
1460
Workhorse Group
WKHS
$33.8M
| $49K | ﹤0.01% |
+4
| New | +$37.4K |
2017 Q2
0 quarters
|
|
1461
Lightpath Technologies
LPTH
$494M
| $46K | ﹤0.01% |
+17,200
| New | +$48.3K |
2017 Q2
0 quarters
|
|
1462
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $45K | ﹤0.01% |
+4,646
| New | +$94.9K |
2017 Q2
0 quarters
|
|
1463
DELISTED
Regulus Therapeutics
RGLS
| $44K | ﹤0.01% |
+370
| New | +$61.8K |
2017 Q2
0 quarters
|
|
|
WCST
1464
DELISTED
Wecast Network, Inc. Common Stock
WCST
| $44K | ﹤0.01% |
+25,034
| New | +$64.5K |
2017 Q2
0 quarters
|
|
1465
Companhia Siderúrgica Nacional
SID
$1.13B
| $43K | ﹤0.01% |
20,147
-1,422
| -7% | -$3.17K |
2016 Q4
2 quarters
|
|
1466
Larimar Therapeutics
LRMR
$248M
| $42K | ﹤0.01% |
+997
| New | +$51K |
2017 Q2
0 quarters
|
|
1467
Theriva Biologics
TOVX
$7.64M
| $40K | ﹤0.01% |
8
+7
| +700% | +$34.9K |
2016 Q4
2 quarters
|
|
1468
DELISTED
Asensus Surgical, Inc.
ASXC
| $39K | ﹤0.01% |
+4,222
| New | +$40.2K |
2017 Q2
0 quarters
|
|
|
KONA
1469
DELISTED
Kona Grill, Inc.
KONA
| $37K | ﹤0.01% |
+10,027
| New | +$46K |
2017 Q2
0 quarters
|
|
|
WAC
1470
DELISTED
Walter Investment Mgt Corp
WAC
| $37K | ﹤0.01% |
+39,503
| New | +$45.5K |
2017 Q2
0 quarters
|
|
|
LTS
1471
DELISTED
Ladenburg Thalmann Financial Services Inc
LTS
| $36K | ﹤0.01% |
+14,905
| New | +$36.1K |
2017 Q2
0 quarters
|
|
|
CYTR
1472
DELISTED
CytRx Corp
CYTR
| $33K | ﹤0.01% |
+8,839
| New | +$30.2K |
2017 Q2
0 quarters
|
|
|
NIHD
1473
DELISTED
NII Holdings, Inc. Common Stock
NIHD
| $33K | ﹤0.01% |
+40,434
| New | +$30.9K |
2017 Q2
0 quarters
|
|
1474
Aptevo Therapeutics
APVO
$2.62M
| – | – |
0
| – | – |
2016 Q3
3 quarters
|
|
1475
DELISTED
DURECT Corp
DRRX
| $32K | ﹤0.01% |
2,050
-149
| -7% | -$1.7K |
2016 Q4
2 quarters
|
|
Similar funds
Squarepoint's Q2 2017 Portfolio in Review
As of Q2 2017, Squarepoint held 2,064 positions worth $5.08B, up 40% from $3.63B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Squarepoint deployed $1.39B of net new capital in Q2 2017, opening 586 new positions and adding to 519 existing holdings. Its largest new stake was iShares MSCI Taiwan ETF: 2,618,387 shares worth $93.6M.
By sector, the portfolio is most concentrated in Miscellaneous at 17% of assets, up from 15% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was State Street SPDR S&P MIDCAP 400 ETF Trust, an estimated $33M trimmed.
- Squarepoint's largest Q2 2017 buy was iShares MSCI Taiwan ETF: 2,618,387 shares worth $93.6M.
- Squarepoint added most to VanEck Gold Miners ETF in Q2 2017, an estimated $71.9M increase.
- Squarepoint's biggest Q2 2017 reduction was State Street SPDR S&P MIDCAP 400 ETF Trust, cutting an estimated $33M.
- Squarepoint fully exited iShares MSCI EAFE ETF in Q2 2017, selling an estimated $26.5M.
- Squarepoint's ten largest holdings make up 16% of its $5.08B portfolio in Q2 2017.
- Squarepoint opened 586 new positions and closed 568 in Q2 2017.
- Squarepoint's portfolio value rose 40% quarter-over-quarter to $5.08B.
Based on Squarepoint's 13F filing for Q2 2017, filed 14 Aug 2017.